Barbara is a myeloma patient and patient advocate. With diplomas in history of art and English-Polish translation, Barbara has established her professional career as a copywriter, editor and translator specialising in law, business and economy. After being diagnosed with multiple myeloma in 2019, she decided to get involved in patient advocacy. The first step was the one-year Advocacy Development Programme organised by Myeloma Patients Europe. The programme led to her becoming actively engaged with MPE projects and voicing the patients’ issues on the European level. Barbara is passionate about the patient’s role in the medical landscape and their right to clear and thorough information. She believes that an illness shouldn’t define anybody, as it is just one of many experiences in a person’s life.
US Food and Drug Administration (FDA) issues draft guidance on minimal residual disease
The US Food and Drug Administration (FDA) has issued draft guidance to the pharmaceutical industry on using minimal residual disease (MRD) and complete response (CR) in myeloma clinical trials as…